Skip to main content
. 2017 Mar 10;12(1):27. doi: 10.1007/s11657-017-0321-8

Table 4.

Type and frequency of adverse events among the study population

Adverse events BIS initiation at week 2 (n = 49) BIS initiation at week 12 (n = 51) p value
Nausea/vomiting 1 1 0.095
Constipation 1
Diarrhea 1
Myalgia 2
Flu-like symptoms 1
Muscle cramp 1
Hearing impairment 1
Deep vein thrombosis 1
Ischemic stroke 1
Total number of adverse events 8 (16.3%) 3 (5.9%)

Data presented as number or number (%); p value <0.05 indicates statistical significance

BIS bisphosphonate